H ng K ng E change and Clea ing Limi ed and The S ck E change f H ng K ng Limi ed ake n e n nsibili f he c n en f hi ann ncemen , make n e en a i n a i acc ac c m le ene and e e di claim an liabili ha e e f an l h e e a ing f m in eliance n he h le an a f he c n en f hi ann ncemen .

HUA MEDICINE

(Inc a ed in he Ca man Island i h limi ed liabili)

(stock code: 2552)

GRANT OF SHARE OPTIONS

Thi ann ncemen i made an R le 17.06A f he R le G e ning he Li ing f Sec i ie n The S ck E change f H ng K ng Limi ed (he "Listing Rules").

The b a d (he "Board") f di ec (he "Directors") f H a Medicine (he "Company") ann nce ha n Ma ch 22, 2021, he C m an g an ed ha e i n (he "Share Options") em l ee f he C m an (he "Grantees") an he C m an 'ha e i n cheme hich a c ndi i nall a ed and ad ed n A g 26, 2018 and effec i e beginning Se embe 14, 2018 (he "Share Option Scheme"), bjec acce ance b he G an ee The Sha e O i n en i le he G an ee b c ibe f a al f 9,000,000 ne ha e i h a n minal al e f US$0.001 each (he

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, save for D. Li Chen (executive Director and chief executive officer of the Company) who has been granted 3,000,000 Share Options, all the the Grantees are either a Director, chief executive or substantial shareholder of the Company or an associate (as defined in the Listing Rules) of any of them. The grant of Share Options to D. Li Chen has been approved by the independent non-executive Directors of the Company.

By Order of the Board
Dr. Li Chen
Chief Executive Officer and Executive Director

Hong Kong, March 22, 2021

As of the date of this announcement, the Board of Directors comprises D. Li Chen and M. Gregory Chien Cheng Lin as executive Directors, M. Robert Talbert Nelsen and D. Lian Ying Chen as non-executive Directors, and M. Walter Teh-ming Kwauk, M. William Robert Keller, M. Junling Liu and M. Yiu Wa Alec Tsui as independent non-executive Directors.